Skip to main content

Table 1 Outcomes for efficacy, net-benefit and safety up to 30 days, 180 days and to maximal follow-up (mean 25 months)

From: Impact of thrombus aspiration during ST-Elevation Myocardial Infarction: a six month composite endpoint and risk of stroke analyses of the TASTE trial

Outcome

Thrombus aspiration N = 3621

PCI alone N = 3623

Hazard ratio (95 % CI)

P-value

Efficacy up to 180 days

    

Cardiovascular (CV) death

125 (3.5 %)

133 (3.7 %)

0.94 (0.74-1.20)

0.62

All cause death

145 (4.0 %)

156 (4.3 %)

0.93 (0.74-1.17)

0.52

Rehospitalisation for new myocardial infarction (Rehosp-MI)

63 (1.7 %)

70 (1.9 %)

0.90 (0.64-1.26)

0.53

Definite stent thrombosis (ST)

20 (0.6 %)

26 (0.7 %)

0.77 (0.42-1.37)

0.37

Target vessel revascularization (TVR)

130 (3.6 %)

144 (4.0 %)

0.90 (0.71-1.14)

0.38

Cardiogenic chock or new hospitalisation with heart failure (HF)

176 (4.9 %)

186 (5.1 %)

0.95 (0.77-1.16)

0.59

CV death, cardiogenic shock, Rehosp-MI or new heart failure (HF)a

316 (8.7 %)

338 (9.3 %)

0.93 (0.80-1.09)

0.36

Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, definite ST or TVR

409 (11.3 %)

448 (12.4 %)

0.91 (0.79-1.04)

0.15

Efficacy during follow-up (median 25 months)

    

Cardiovascular death

215 (5.9 %)

229 (6.3 %)

0.94 (0.78 - 1.13)

0.51

Cardiovascular death, cardiogenic shock, Rehosp-MI or new HFa

483 (13.3 %)

521 (14.4 %)

0.92 (0.82-1.05)

0.21

Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, definite ST or TVR

615 (17.0 %)

678 (18.7 %)

0.90 (0.81-1.00)

0.058

Safety

    

Stroke up to 30 days

24 (0.7 %)

27 (0.7 %)

0.89 (0.51-1.54)

0.68

Stroke up to 180 days

42 (1.2 %)

45 (1.2 %)

0.93 (0.61-1.42)

0.75

Stroke until follow up (median 25 months)

89 (2.5 %)

89 (2.5 %)

1.00 (0.75-1.34)

0.99

Net-benefit up to 180 days

    

Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, or strokeb

343 (9.5 %)

371 (10.2 %)

0.92 (079-1.07)

0.27

Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, stroke, definite ST or TVRc

436 (12.0 %)

479 (13.2 %)

0.90 (0.79-1.03)

0.12

Net-benefit during follow-up (median 25 months)

    

Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, or strokeb

545 (15.1 %)

582 (16.1 %)

0.93 (0.83-1.05)

0.24

Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, stroke, definite ST or TVRc

677 (18.7 %)

736 (20.3 %)

0.91 (0.82-1.01)

0.08

  1. aDenotes the primary quadruple composite endpoint within 180 days and also the same quadruple endpoint, during follow up (median 25 months)
  2. bDenotes the net-benefit composite endpoint up to 180 days and during follow-up
  3. cDenotes the extended net-benefit composite endpoint within 180 days and during follow-up
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us